The Supreme Court’s decision in Amgen Inc. v. Sanofi found that antibody claims defined by their binding and blocking function lacked enablement..The consensus seems to be that Amgen generally forecloses broad genus claims in the biotechnology field.
I’m a bit behind and therefore am not part of the slew of commentary that flowed from the Supreme Court’s decision in Amgen Inc. v. Sanofi, 143 S. Ct. 1243, 1248 (2023), addressing.